Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for MDGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2026 838.91M
March 31, 2026 817.93M
December 31, 2025 988.65M
September 30, 2025 1.115B
June 30, 2025 802.02M
March 31, 2025 848.07M
December 31, 2024 931.25M
September 30, 2024 1.004B
June 30, 2024 1.063B
March 31, 2024 1.059B
December 31, 2023 634.13M
September 30, 2023 232.35M
June 30, 2023 298.42M
March 31, 2023 329.48M
December 31, 2022 358.77M
September 30, 2022 153.19M
June 30, 2022 211.77M
March 31, 2022 219.95M
December 31, 2021 270.35M
September 30, 2021 299.14M
June 30, 2021 323.85M
March 31, 2021 307.22M
December 31, 2020 284.15M
September 30, 2020 335.94M
June 30, 2020 384.38M
Date Value
March 31, 2020 408.51M
December 31, 2019 439.04M
September 30, 2019 453.61M
June 30, 2019 466.40M
March 31, 2019 477.82M
December 31, 2018 483.72M
September 30, 2018 488.54M
June 30, 2018 490.30M
March 31, 2018 182.82M
December 31, 2017 191.53M
September 30, 2017 62.14M
June 30, 2017 67.17M
March 31, 2017 40.13M
December 31, 2016 40.50M
September 30, 2016 39.56M
June 30, 2016 43.02M
March 31, 2016 52.04M
December 31, 2015 0.3062M
September 30, 2015 88.25M
June 30, 2015 98.33M
March 31, 2015 76.61M
December 31, 2014 97.69M
September 30, 2014 119.28M
June 30, 2014 112.06M
March 31, 2014 78.79M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 839.38M
Karyopharm Therapeutics, Inc. 65.10M
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B
Anika Therapeutics, Inc. 38.41M